ERBB2 and breast cancer: Importantly, CCNE-high, HER2+ tumors were sensitive to CDK2/9 inhibition [59,60], supporting the potential for CDK inhibitor therapy to serve as promising modality for the treatment of trastuzumab resistant HER2+ breast cancer.